Clinical evidence and potential neurobiological underpinnings of unresolved symptoms of depression
- PMID: 18363453
- DOI: 10.4088/jcp.v69n0211
Clinical evidence and potential neurobiological underpinnings of unresolved symptoms of depression
Abstract
Objective: Recent data indicate that more than 65% of patients with major depressive disorder (MDD) fail to achieve remission. This article reviews research on the current understanding and management of residual symptoms, i.e., subthreshold depressive symptoms present after recovery from a major depressive episode.
Data sources: MEDLINE (1966 to June 2006) was searched using combinations of the following search terms: major depressive disorder, residual symptoms, remission, response, tachyphylaxis, antidepressant, algorithm, treatment, responsiveness, serotonin, norepinephrine, and dopamine.
Study selection: All relevant articles that were published in English and reported original study data related to residual symptoms in MDD were included.
Data extraction: Studies were examined for data related to the prevalence, presentation, consequences, treatment, and neurobiological underpinnings of residual symptoms associated with MDD.
Data synthesis: Residual symptoms are common among patients treated for MDD who do not achieve full remission. Incomplete remission is associated with increased risk of relapse, suicide, functional impairment, and higher use of health care resources. Several factors, including "downstream" neurochemical mechanisms and clinical factors such as lack of adherence, contribute to the high prevalence of residual symptoms. Various clinical strategies, including switching and substitution antidepressant therapies, are used to address unresolved depressive symptoms. Individual differences in therapeutic response contribute to inadequate treatment and are linked to numerous clinical and neurobiological factors, including noncompliance, underdosing, intolerance, disturbances in neural circuitry, and genetic variability in neurotransmitters.
Conclusions: Future research is needed to more precisely characterize residual symptoms and their underlying biochemical and molecular mechanisms in order to develop more effective treatment methods.
Similar articles
-
The other face of depression, reduced positive affect: the role of catecholamines in causation and cure.J Psychopharmacol. 2007 Jul;21(5):461-71. doi: 10.1177/0269881106069938. Epub 2006 Oct 18. J Psychopharmacol. 2007. PMID: 17050654 Review.
-
Noradrenaline and serotonin reuptake inhibition as clinical principles: a review of antidepressant efficacy.Acta Psychiatr Scand Suppl. 2000;402:28-36. doi: 10.1034/j.1600-0447.2000.02605.x. Acta Psychiatr Scand Suppl. 2000. PMID: 10901156 Review.
-
The novel triple reuptake inhibitor JZAD-IV-22 exhibits an antidepressant pharmacological profile without locomotor stimulant or sensitization properties.J Pharmacol Exp Ther. 2010 Dec;335(3):762-70. doi: 10.1124/jpet.110.174011. Epub 2010 Sep 23. J Pharmacol Exp Ther. 2010. PMID: 20864506 Free PMC article.
-
[Domino principle--monoamines in bottom-view].Neuropsychopharmacol Hung. 2008 Jun;10(3):131-40. Neuropsychopharmacol Hung. 2008. PMID: 18956617 Review. Hungarian.
-
Differences in mechanism of action between current and future antidepressants.J Clin Psychiatry. 2003;64 Suppl 13:13-7. J Clin Psychiatry. 2003. PMID: 14552651 Review.
Cited by
-
Adult ADHD and comorbid disorders: clinical implications of a dimensional approach.BMC Psychiatry. 2017 Aug 22;17(1):302. doi: 10.1186/s12888-017-1463-3. BMC Psychiatry. 2017. PMID: 28830387 Free PMC article. Review.
-
The association of ARRB1 polymorphisms with response to antidepressant treatment in depressed patients.Front Pharmacol. 2022 Oct 26;13:974570. doi: 10.3389/fphar.2022.974570. eCollection 2022. Front Pharmacol. 2022. PMID: 36386175 Free PMC article.
-
Inflammation Effects on Motivation and Motor Activity: Role of Dopamine.Neuropsychopharmacology. 2017 Jan;42(1):216-241. doi: 10.1038/npp.2016.143. Epub 2016 Aug 2. Neuropsychopharmacology. 2017. PMID: 27480574 Free PMC article. Review.
-
Defining cognitive profiles of depressive patients using the Brief Assessment of Cognition in Affective Disorders.PeerJ. 2019 Aug 1;7:e7432. doi: 10.7717/peerj.7432. eCollection 2019. PeerJ. 2019. PMID: 31396459 Free PMC article.
-
Examining the efficacy of adjunctive aripiprazole in major depressive disorder: a pooled analysis of 2 studies.Prim Care Companion J Clin Psychiatry. 2008;10(6):440-7. doi: 10.4088/pcc.v10n0603. Prim Care Companion J Clin Psychiatry. 2008. PMID: 19287552 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical